{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:17:39Z","timestamp":1789186659125,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010902","name":"Vanda Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010902","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016186","name":"DalCor Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaip.2022.02.026","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T23:23:40Z","timestamp":1646609020000},"page":"1515-1526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases"],"prefix":"10.1016","volume":"10","author":[{"given":"G. Walter","family":"Canonica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Desrosiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Daizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhesh","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif H.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda P.","family":"Mannent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Djandji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.02.026_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pupt.2015.02.007","article-title":"Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD","volume":"31","author":"Cazzola","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.02.026_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","article-title":"New targets for rapid antidepressant action","volume":"152","author":"Machado-Vieira","year":"2017","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jaip.2022.02.026_bib3","first-page":"247","article-title":"Onset of action of biologics in patients with moderate-to-severe psoriasis","volume":"17","author":"Papp","year":"2017","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2022.02.026_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12948-017-0067-2","article-title":"Asthma management among allergists in Italy: results from a survey","volume":"15","author":"Magnoni","year":"2017","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaip.2022.02.026_bib5","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.02.026_bib6","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.02.026_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.026_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40272-020-00387-2","article-title":"Dupilumab to treat type 2 inflammatory diseases in children and adolescents","volume":"22","author":"Licari","year":"2020","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jaip.2022.02.026_bib9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.026_bib10","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.02.026_bib11","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.026_bib12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.02.026_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2022.02.026_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2022.02.026_bib16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.19457","article-title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.026_bib17","first-page":"S98","article-title":"Validation of the Peak Pruritus Numerical Rating Scale (NRS) in adolescent moderate-to-severe atopic dermatitis patients for use in clinical trials","volume":"27","author":"Yosipovitch","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.02.026_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2022.02.026_bib19","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.02.026_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0031-9384(84)90269-5","article-title":"Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function","volume":"32","author":"Doty","year":"1984","journal-title":"Physiol Behav"},{"key":"10.1016\/j.jaip.2022.02.026_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.026_bib22","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.026_bib23","author":"Beck"},{"key":"10.1016\/j.jaip.2022.02.026_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.02.026_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.026_bib26","first-page":"4613","article-title":"Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE","volume":"56","author":"Wechsler","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.02.026_bib27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry","volume":"84","author":"Ari\u00ebns","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.026_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jaad.2019.12.034","article-title":"Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States","volume":"82","author":"Khosravi","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.026_bib29","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.pupt.2020.101965","article-title":"Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps","volume":"64","author":"Matsuno","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.02.026_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaip.2022.02.026_bib31","doi-asserted-by":"crossref","first-page":"101830","DOI":"10.1016\/j.pupt.2019.101830","article-title":"Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose","volume":"58","author":"Pelaia","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.02.026_bib32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.anai.2019.02.016","article-title":"Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma","volume":"122","author":"Chupp","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.02.026_bib33","doi-asserted-by":"crossref","first-page":"AB55","DOI":"10.1016\/j.jaci.2020.12.224","article-title":"Real-world rapid response to mepolizumab in the uncontrolled T2 severe asthma endotype","volume":"147","author":"Perez","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.026_bib34","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaip.2022.02.026_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.47102\/annals-acadmedsg.V33N3p311","article-title":"Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study","volume":"33","author":"Lee","year":"2004","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.jaip.2022.02.026_bib36","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/npjpcrm.2015.4","article-title":"Why aren\u2019t we doing better in asthma: time for personalised medicine?","volume":"25","author":"Thomas","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaip.2022.02.026_bib37","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","article-title":"Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD","volume":"107","author":"M\u00e4kel\u00e4","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.02.026_bib38","first-page":"397","article-title":"A\u00a0review of patient adherence to topical therapies for treatment of atopic dermatitis","volume":"96","author":"Snyder","year":"2015","journal-title":"Cutis"},{"key":"10.1016\/j.jaip.2022.02.026_bib39","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.026_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822002276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822002276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:33:44Z","timestamp":1761975224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822002276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2213219822002276"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.026","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}